Analyst Profile

Followed by 158 followers
.
Mani Foroohar

Mani Foroohar

SVB Securities
Wall Street Analyst
#7,974 out of 8,141 Wall Street Analysts
#23,704 out of 24,284 experts

Success Rate

39%
84 out of 213 transactions made a profit

Average Return

-15.30%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
Copying Mani Foroohar's trades since 2020 and holding each position for 1 Year would result in 39.44% of your transactions generating a profit, with an average return of -15.3% per rating.

Stock Rating Distribution

508Ratings
51.97% Buy
39.96% Hold
8.07% Sell
Distribution of Mani Foroohar's ratings

Additional Information

Main Sector:General
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
Intellia Therapeutics Inc
(NTLA)
Rating:Buy
Date:Nov 05, 2020 - Nov 05, 2021
Return:+375.70%
The most profitable rating made by Mani Foroohar

Mani Foroohar's Stock Coverage

Company
Date
Position
Action
Price Target
No. of Ratings
Success Rate
Avg. Return
EIDX
Eidos Therapeutics
Oct 05, 2020
Hold
Downgraded
4Ratings
67%
+42.93%
Sarepta Therapeutics
Nov 06, 2020
Buy
Reiterated
$197.00
(71.95% Upside)
3Ratings
33%
-1.53%
Adverum Biotechnologies
Oct 11, 2021
Hold
Reiterated
11Ratings
25%
-49.50%
Avrobio
Oct 19, 2021
Hold
Reiterated
7Ratings
0.00%
DRNA
Dicerna Pharma
Nov 14, 2021
Buy
Reiterated
16Ratings
100%
+46.19%
Sio Gene Therapies
Feb 11, 2022
Hold
Reiterated
$1.00
(221.75% Upside)
9Ratings
0%
-49.03%
RegenXBio
Nov 03, 2022
Hold
Reiterated
$14.00
(-38.08% Downside)
28Ratings
100%
+43.70%
Rocket Pharmaceuticals
Nov 03, 2022
Buy
Reiterated
$56.00
(201.08% Upside)
28Ratings
44%
-17.99%
Moderna
Nov 03, 2022
Hold
Reiterated
$101.00
(-42.74% Downside)
46Ratings
74%
-36.07%
Amryt Pharma
Nov 03, 2022
Buy
Reiterated
$19.00
(168.36% Upside)
14Ratings
18%
-14.43%
List of latest recommendations made by Mani Foroohar. Click to expand and see Mani Foroohar's performance on a particular stock
Disclaimer: TipRanks collects analysts’ ratings and price targets by scanning publicly available reports on financial websites and by receiving reports from analysts, firms, or customers. The information and statistics displayed might not be accurate, complete, or up-to-date. The analyst ratings provided are the sole responsibility of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings, or opinions expressed.
Send Us Reports
If you receive reports that you think we are missing, we will thank you with a free Ultimate upgrade!
Learn More >